Havas Health and BrightInsight Form Partnership

Havas Health announced an exclusive strategic partnership with BrightInsight, a digital platform for biopharma. The alliance aims to address patient adherence and persistence issues in the pharmaceutical industry, a problem estimated to be worth over $500 billion.

- This exclusive agreement designates Havas Health as BrightInsight's sole global agency partner, creating a combined offering of strategy, creative, and a compliant digital platform. - A key objective of the alliance is to bridge the gap between a patient receiving a prescription and that treatment being effective in a real-world setting. - BrightInsight's technology has demonstrated the ability to improve patient adherence to their prescribed therapy by four percentage points over traditional patient support programs. - The partnership is a component of Havas Health's "Converged" strategy, which focuses on blending human insight with advanced technology. - Jeff Hoffman, Chief Development Officer for the Havas Health Network, noted that this provides clients with a "pre-vetted, regulatory-ready engine" to make a patient's brand experience more meaningful. - The BrightInsight platform is built with pre-existing functionalities that can meet 60-80% of what clients typically require, which can speed up the time to market for digital health tools by 6 to 24 months. - Havas Health has a history of developing award-winning campaigns, such as the "ParkinSex" initiative for the American Parkinson Disease Association, which earned "Best in Show" at the 2023 Medical Marketing + Media awards. - BrightInsight's platform is designed for global scalability and is ready for deployment in over 64 countries with localization into more than 25 languages.

Get your own daily briefing

Scout delivers personalized news, insights, and conversations tailored to your role and industry.

Download on the App Store

Shared from Scout - Be the smartest in the room.